Investigational drug · Phase 3
NTQ1062
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "NTQ1062"
First trial start
2026
Feb 10, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NTQ1062", any sponsor or status.
Conditions studied
As listed on its trial records.
- HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NTQ1062" as an intervention, largest first.
- A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast CancerPivotal-lookingNot yet recruiting
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT07393321 · 210 participants (planned) · Start Feb 10, 2026 · Primary completion Aug 31, 2028
Drug: Placebo + fulvestrant; NTQ1062+Fulvestrant · For: HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT06172322 · 42 participants (planned) · Start Dec 28, 2023 · Primary completion Apr 2025
Drug: NTQ1062 with Fulvestrant · For: HR Positive/HER-2 Negative Breast Cancer
Sites: Shanghai, China
Nanjing Chia-tai Tianqing PharmaceuticalIndustry
NCT06172309 · 32 participants · Start Sep 24, 2021 · Primary completion Apr 20, 2024
Drug: NTQ1062 · For: Advanced Solid Tumors
Sites: Jinan, China; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- AI-assisted molecular docking and molecular dynamics simulations for predicting off-target effects of AKT1 ATP-competitive inhibitors.
Huang J, Pan Y, Fan F, et al. · J Biomol Struct Dyn 2026
- Deciphering the Medicinal Chemistry Aspects of Akt Inhibitors for the Management of Cancer: Structure-Activity Relationship Frameworks, Landscapes, and Optimization Approaches.
Dhangar MS, Palkar MB · Chem Biodivers 2026
- Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors.
Ma C, Wu J, Wang L, et al. · J Med Chem 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.